B'Soleil Inc, a provider of healthy immune boosters, said on Tuesday that despite the current approach to stop the spread of the COVID-19 that includes lockdown, masks, mandates, physical distancing, vaccinations, quarantine, contact tracing and contact testing, self-isolating and testing individuals, the virus continues unabated, incubating in people, as well as mutating and spreading.
In addition to the current policy, the company advises that individuals who test positive for the COVID-19 and their contacts should use the B'Soleil immune booster supplement that improves the immune defense within a few days. Other products with a similar proven ingredients could be used.
Unlike other immune support vitamins, B'Soleil is unique blend of natural ingredients that creates a safe and potent combination that boost the body's immune system to fight against viruses and other illnesses. It contains a gluten-free, allergen-free and non-GMO blend of fruits and vegetables including pineapple, lemon, ginger and lime. This supplement is fortified with bromelain, vitamin C, D and Zinc.
According to the company, anti-inflammatory properties and other ingredients in the B'Soleil are known to powerfully help the immune system to fight against multi-system inflammation, which is one of the serious conditions associated with most viruses.
Within only a few days of use, B'Soleil reportedly enhances the immune function and provides advanced defenses against viruses and other illnesses. Each vegetable capsule has ingredients known to accelerate the body's healing process, including bromelain, pineapple and vitamin C.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins